

June 02, 2017

Discovery Laboratories Private Limited

Summary of rated instruments

Instrument*	Rated Amount (in crore)	Rating Action
Fund-based – Cash Credit	6.25	[ICRA]B (Stable); Reaffirmed
Total	6.25	

*Instrument details are provided in Annexure-1

Rating action

ICRA has reaffirmed the long-term rating of [ICRA]B (pronounced ICRA B)¹ assigned to the Rs. 6.25 crore² fund-based bank facilities of Discovery Laboratories Private Limited (DLPL). The outlook on the long term is stable.

Rationale

The reaffirmation of the rating is constrained by the company's small scale of operations in pharmaceuticals industry; drop in turnover from Rs. 42.74 crore in FY2016 to Rs. 38.63 crore in FY2017 due to lower sales and job work income from Mylan Laboratories; and high customer concentration risk with top five customers accounting for ~90% of the total sales. The rating is also constrained by the project execution risk with the company increasing the capacity from 100 kilo liters to 180 kilo liters coupled with ~85% of the project cost yet to be incurred and adverse impact on the cash flows and coverage metrics in the near term; tight liquidity profile of the company as reflected from high working capital limits utilization in the past twelve months; and highly fragmented and competitive nature of the industry which limits the pricing flexibility. The rating, however, positively considers long experience of promoters' in Active Pharmaceutical Ingredient (API) manufacturing industry and the diverse product portfolio of the company which includes various intermediates used in API manufacturing; ICRA also notes the company's strategic partnership with reputed pharmaceutical companies such as Dr. Reddy's Laboratories and Mylan Laboratories which supports company's revenues to an extent.

Going forward, the firm's ability to timely complete the capex without cost overruns while effectively managing its working capital cycle shall be the key credit rating sensitivity.

Key rating drivers

Credit strengths

- Long experience of the promoters in the pharmaceutical intermediates manufacturing industry
- Strategic partnership with reputed clientele like Dr. Reddy's Laboratories Limited (DRL), Mylan Laboratories Limited
- Product portfolio includes intermediates used for manufacturing widely used bulk drugs ensuring a stable demand

¹ For complete rating scale and definitions, please refer to ICRA's website www.icra.in or other ICRA Rating Publications

² 100 lakh = 1 crore = 10 million

Credit weaknesses

- Substantial debt funded capex to be incurred over the next 18 months is expected to affect the leverage and coverage metrics adversely; further project is vulnerable to cost and time overruns given that 87% of the project cost is yet to be incurred as on March 31, 2017
- Drop in turnover from Rs. 42.74 crore in FY2016 to Rs. 38.63 crore in FY2017 due to lower sales to Mylan Laboratories Ltd
- Highly fragmented and competitive nature of the API industry limits pricing flexibility
- High customer concentration risk given that top-5 customers account for ~ 90% of the total revenues in the last 2 years
- Tight liquidity profile of the company in the last 12 months as reflected by ~90% utilization of working capital limits owing to high inventory and debtor levels
- Modest scale of operations with turnover of less than Rs. 40 crore for FY2017

Description of key rating drivers:

DLPL is involved in manufacturing of APIs used in the manufacturing of drugs. DLPL was incorporated in 2004 and is being managed by Mr. Prashanth Manne who has more than a decade experience in pharmaceutical industry. The company sells its products primarily to Mylan Labs and DRL and has a strategic partnership with these companies for manufacturing APIs under various therapeutic segments. Further, the company also manufactures intermediates used for manufacturing widely used bulk drugs ensuring a stable demand.

The company is currently undertaking a capacity expansion to increase the total reactor capacity to 180 kilo liters from 100 kilo liters besides adding a pilot plant facility to manufacture new range of intermediates across different therapeutic segments. The estimated cost to be incurred is about Rs 20.97 crore funded by Rs. 5.04 crore promoters' funds (24%), Rs. 3.38 crore internal accruals (16%), and Rs. 12.62 crore term loan from Telangana State Financial Corporation Ltd (60%). The company has incurred a cost of Rs. 2.70 crore till March 31, 2017 which translates to 13% of the total project cost. Hence the project is vulnerable to time and cost overruns. Further, the company's financial performance in FY2017 was modest with turnover dropping to Rs. 38.67 crore in FY2017 from Rs. 42.74 crore in FY2016 due to lower sales to Mylan Laboratories while the liquidity profile remained tight owing to high inventory and debtor levels.

Analytical approach: For arriving at the ratings, ICRA has applied its rating methodologies as indicated below.

Links to applicable criteria:

[Corporate Credit Rating Methodology](#)

[Rating Methodology for Pharmaceutical companies](#)

About the firm:

Incorporated in 2004, Discovery Laboratories Private Limited (DLPL) is engaged in the manufacturing of pharmaceutical intermediates. The name of the company changed from Discovery Intermediates Private Limited to DLPL in January 2017. The company manufactures various types of intermediates and supplies to bulk drug manufacturers in Hyderabad. The company is promoted by Mr. M.V. Sekhara Rao and his son Mr. Prashanth Manne. The company's manufacturing facility is based in Hyderabad (Andhra Pradesh) and the commercial production for the unit commenced in 2006.

As per provisional financials for FY2017, the company reported a profit before tax of Rs. 1.73 crore on an operating income of Rs. 38.63 crore, as against a net profit of Rs. 1.36 crore on an operating income of Rs. 42.74 crore in the previous year.

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years:

Table:

S. No.	Instrument	Current Rating (FY2018)			Chronology of Rating History for the past 3 years		
		Type	Amount Rated (Rs. Crore)	Date & Rating	Date & Rating in FY2017	Date & Rating in FY2016	Date & Rating in FY2015
				June 2017	Jun 2016	Mar 2015	-
1	Cash Credit	Long Term	6.25	[ICRA]B (Stable)	[ICRA]B	[ICRA]B-	-

Complexity level of the rated instrument:

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website www.icra.in

Annexure-1
Instrument Details

Instrument	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. Crore)	Current Rating and Outlook
Cash Credit	-	-	-	6.25	[ICRA]B (Stable)

Source: DLPL

Contact Details

Analyst Contacts

Ravichandran K

044-4596 4301

ravichandran@icraindia.com**Srinivasan R**

044-4596 4315

r.srinivasan@icraindia.com**Vinay Kumar G**

040-4067 6533

vinay.g@icraindia.com**Ruthwik Reddy C**

040-4067 6532

ruthwik.c@icraindia.com

Relationship Contact

Jayanta Chatterjee

080 4332 6401

jayantac@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

© Copyright, 2017, ICRA Limited. All Rights Reserved
Contents may be used freely with due acknowledgement to ICRA

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.

**Registered Office****ICRA Limited**

1105, Kailash Building, 11th Floor, 26, Kasturba Gandhi Marg, New Delhi 110001
Tel: +91-11-23357940-50, Fax: +91-11-23357014

Corporate Office**Mr. Vivek Mathur**

Mobile: +91 9871221122

Email: vivek@icraindia.com

Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002
Ph: +91-124-4545310 (D), 4545300 / 4545800 (B) Fax; +91- 124-4050424

Mumbai**Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: shivakumar@icraindia.com

3rd Floor, Electric Mansion
Appasaheb Marathe Marg, Prabhadevi
Mumbai—400025,
Board : +91-22-61796300; Fax: +91-22-24331390

Kolkata**Mr. Jayanta Roy**

Mobile: +91 9903394664

Email: jayanta@icraindia.com

A-10 & 11, 3rd Floor, FMC Fortuna
234/3A, A.J.C. Bose Road
Kolkata—700020
Tel +91-33-22876617/8839 22800008/22831411,
Fax +91-33-22870728

Chennai**Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: jayantac@icraindia.com

5th Floor, Karumuttu Centre
634 Anna Salai, Nandanam
Chennai—600035
Tel: +91-44-45964300; Fax: +91-44 24343663

Bangalore**Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: jayantac@icraindia.com

'The Millenia'
Tower B, Unit No. 1004, 10th Floor, Level 2 12-14, 1 & 2,
Murphy Road, Bangalore 560 008
Tel: +91-80-43326400; Fax: +91-80-43326409

Ahmedabad**Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: shivakumar@icraindia.com

907 & 908 Sakar -II, Ellisbridge,
Ahmedabad- 380006
Tel: +91-79-26585049, 26585494, 26584924; Fax:
+91-79-25569231

Pune**Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: shivakumar@icraindia.com

5A, 5th Floor, Symphony, S.No. 210, CTS 3202, Range
Hills Road, Shivajinagar, Pune-411 020
Tel: + 91-20-25561194-25560196; Fax: +91-20-
25561231

Hyderabad**Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: jayantac@icraindia.com

4th Floor, Shobhan, 6-3-927/A&B. Somajiguda, Raj
Bhavan Road, Hyderabad—500083
Tel:- +91-40-40676500